查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1974443

人工智慧市場分析及預測（至2035年）：預測藥物反應建模－按類型、產品類型、服務、技術、組件、應用、最終用戶、功能、部署模式和解決方案分類

AI for Predictive Drug Response Modeling Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, End User, Functionality, Deployment, Solutions
出版日期: | 出版商: Global Insight Services | 英文 369 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

用於預測藥物反應建模的人工智慧市場預計將從2024年的23億美元成長到2034年的36億美元，複合年成長率約為4.6%。該市場涵蓋利用人工智慧預測患者藥物反應並改善精準醫療的技術。它將機器學習演算法與生物醫學數據相結合，以最佳化藥物療效和安全性。對個人化醫療日益成長的需求以及人工智慧驅動的分析技術的進步正在推動計算生物學和醫療資訊學領域的成長和創新。

全球人工智慧藥物反應預測建模市場正受到關稅、地緣政治風險和不斷變化的供應鏈趨勢等多重因素的複雜影響。在日本和韓國，對人工智慧相關進口產品徵收關稅促使兩國戰略轉向加強國內研發能力，並推動人工智慧驅動的醫療健康解決方案創新。為因應出口限制，中國大力推動人工智慧技術自主研發，並投入大量資金發展國內人工智慧技術。台灣作為半導體強國，面臨可能削弱其市場關鍵地位的地緣政治不確定性。在全球範圍內，受個人化醫療和先進分析技術需求的驅動，母市場正經歷強勁成長。到2035年，市場擴張將取決於穩健的供應鏈和戰略夥伴關係，而中東衝突可能會影響能源價格和製造成本。

市場區隔
類型 機器學習、深度學習、自然語言處理
產品 軟體平台、人工智慧演算法、資料管理工具
服務 諮詢、整合和實施、支援和維護、培訓和教育
科技 雲端部署、本地部署、混合部署
成分 硬體、軟體、服務
應用 腫瘤學、心臟病學、神經病學、感染疾病、免疫學
最終用戶 製藥公司、生技公司、研究機構、醫療保健機構
功能 預測分析、資料探勘、模擬
實施表格 大型企業、中小企業
解決方案 客製化解決方案，標準解決方案

受個人化醫療和數據分析技術進步的推動，用於預測藥物反應建模的人工智慧市場正經歷強勁成長。其中，軟體領域成長最為迅猛，這主要得益於機器學習演算法和人工智慧平台的整合，從而提高了預測精度。特別是，人工智慧驅動的分析工具和機器學習框架處於領先地位，透過個人化治療方案，幫助改善患者預後。

硬體領域位居第二，專注於人工智慧最佳化處理器和資料儲存解決方案，以支援複雜的運算需求。這些技術對於處理預測建模所需的海量資料集至關重要。此外，儘管雲端解決方案因其擴充性和成本效益而日益普及，但本地部署系統對於資料敏感型應用仍然不可或缺。人工智慧與生物技術的融合不斷開啟新的可能性，推動創新並加速市場發展。製藥公司與人工智慧技術供應商之間日益密切的合作進一步促進了這一趨勢。

用於預測藥物反應建模的人工智慧市場呈現出動態的市場環境，包括市場佔有率分佈、定價策略和新產品推出。各公司對客戶需求和競爭壓力有著敏銳的洞察力，並積極採用創新的定價模式來擴大市場佔有率。科技的快速進步和對個人化醫療解決方案日益成長的需求，推動了新產品的湧現。這為創新創造了有利的環境，各公司競相透過不斷改進產品線來超越競爭對手。

該市場競爭異常激烈，主要企業透過策略聯盟和收購爭奪主導。與行業巨頭相比，規模較小的公司正利用其專業優勢和靈活應變能力，建立獨特的市場地位。監管的影響至關重要，北美和歐洲嚴格的政策塑造了競爭格局。這些法規在確保高標準的同時，也對新進入者構成了障礙。市場分析顯示，監管協調的趨勢正在顯現，預計將提高營運效率，並促進跨境創新。

主要趨勢和促進因素：

人工智慧和機器學習技術的進步推動了藥物反應預測建模領域的市場快速成長。運算能力的提升和先進演算法的出現，使得藥物反應預測更加精準，並顯著縮短了研發週期。隨著製藥公司尋求高效且經濟的解決方案，將人工智慧融入藥物研發流程變得至關重要。

一個關鍵趨勢是個人化醫療的興起，它利用人工智慧根據個人基因譜客製化治療方案。基因組學和生物技術領域投資的增加推動了這一趨勢的發展。監管機構正積極應對這些技術進步，提供既能促進創新又能確保病人安全的框架。

此外，科技公司與醫療服務提供者之間的合作正在推動創新人工智慧平台的發展。這些夥伴關係旨在提高預測準確性並改善患者療效。隨著藥物研發領域對預測建模的需求持續成長，能夠提供擴充性且穩健的人工智慧解決方案的公司將迎來許多機會。

限制與挑戰：

用於預測藥物反應建模的人工智慧市場目前面臨許多重大限制和挑戰。其中一項主要挑戰是監管環境的複雜性，阻礙了人工智慧技術快速融入醫療保健系統。遵守各種國際標準也增加了難度，減緩了市場滲透速度。此外，精通人工智慧和藥理學的專業人才嚴重短缺，也成為創新和應用的瓶頸。

資料隱私問題也是一大障礙。如何在利用人工智慧進行預測建模的同時確保敏感醫療數據的機密性，仍然是一項重大挑戰，而世界各地不同的資料保護條例更使這項挑戰雪上加霜。

此外，人工智慧技術實施成本高昂，限制了其廣泛應用，尤其是在中小型製藥公司和研究機構。這些成本不僅包括初始投資，還包括持續的維護和更新費用。

互通性也是一個重大挑戰：將人工智慧系統整合到現有的醫療保健基礎設施中常常會遇到技術難題，阻礙無縫運作。

最後，醫療專業人員的懷疑態度也是市場面臨的一大挑戰。他們可能不願相信人工智慧的預測結果，而更傾向於傳統方法。因此，建立人們對人工智慧準確性和可靠性的信心，對於人工智慧的廣泛接受和應用至關重要。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制因素
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 機器學習
    • 深度學習
    • 自然語言處理
  • 市場規模及預測：依產品分類
    • 軟體平台
    • 人工智慧演算法
    • 資料管理工具
  • 市場規模及預測：依服務分類
    • 諮詢
    • 整合與實施
    • 支援與維護
    • 培訓和教育
  • 市場規模及預測：依技術分類
    • 基於雲端的
    • 本地部署
    • 混合
  • 市場規模及預測：依組件分類
    • 硬體
    • 軟體
    • 服務
  • 市場規模及預測：依應用領域分類
    • 腫瘤學
    • 心臟病學
    • 神經病學
    • 感染疾病
    • 免疫學
  • 市場規模及預測：依最終用戶分類
    • 製藥公司
    • 生技公司
    • 研究所
    • 醫療保健提供者
  • 市場規模及預測：依功能分類
    • 預測分析
    • 資料探勘
    • 模擬
  • 市場規模及預測：依發展狀況
    • 主要企業
    • 小型企業
  • 市場規模及預測：按解決方案分類
    • 客製化解決方案
    • 標準溶液

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 供需差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章：公司簡介

  • Atomwise
  • Exscientia
  • Benevolent AI
  • Insilico Medicine
  • Recursion Pharmaceuticals
  • Numerate
  • Cyclica
  • Deep Genomics
  • Berg Health
  • GNS Healthcare
  • Bio Symetrics
  • Owkin
  • Standigm
  • Xtal Pi
  • Two XAR
  • Aria Pharmaceuticals
  • Aiforia Technologies
  • Verge Genomics
  • Aigenpulse
  • Quibim

第9章 關於我們

簡介目錄
Product Code: GIS32706

AI for Predictive Drug Response Modeling Market is anticipated to expand from $2.3 Billion in 2024 to $3.6 Billion by 2034, growing at a CAGR of approximately 4.6%. The AI for Predictive Drug Response Modeling Market encompasses technologies that leverage artificial intelligence to forecast patient responses to pharmaceuticals, enhancing precision medicine. This market integrates machine learning algorithms with biomedical data, aiming to optimize drug efficacy and safety. Increasing demand for personalized treatment and advancements in AI-driven analytics are propelling growth, fostering innovations in computational biology and healthcare informatics.

The global AI for Predictive Drug Response Modeling Market is intricately influenced by tariffs, geopolitical risks, and evolving supply chain trends. In Japan and South Korea, the imposition of tariffs on AI-related imports is prompting a strategic pivot towards enhancing local R&D capabilities and fostering innovation in AI-driven healthcare solutions. China's response to export restrictions involves a robust push towards self-reliance, investing heavily in domestic AI advancements. Taiwan, while a semiconductor powerhouse, faces geopolitical uncertainties that could disrupt its pivotal role in the market. Globally, the parent market is experiencing robust growth, driven by the demand for personalized medicine and advanced analytics. By 2035, the market's expansion will hinge on resilient supply chains and strategic alliances, with Middle East conflicts potentially affecting energy prices and manufacturing costs.

Market Segmentation
TypeMachine Learning, Deep Learning, Natural Language Processing
ProductSoftware Platforms, AI Algorithms, Data Management Tools
ServicesConsulting, Integration and Implementation, Support and Maintenance, Training and Education
TechnologyCloud-based, On-premise, Hybrid
ComponentHardware, Software, Services
ApplicationOncology, Cardiology, Neurology, Infectious Diseases, Immunology
End UserPharmaceutical Companies, Biotechnology Firms, Research Institutes, Healthcare Providers
FunctionalityPredictive Analytics, Data Mining, Simulation
DeploymentLarge Enterprises, SMEs
SolutionsCustomized Solutions, Standard Solutions

The AI for Predictive Drug Response Modeling Market is experiencing robust growth, propelled by advancements in personalized medicine and data analytics. Within this market, the software segment emerges as the top-performing category, driven by the integration of machine learning algorithms and AI platforms that enhance predictive accuracy. Particularly, AI-driven analytics tools and machine learning frameworks are at the forefront, facilitating better patient outcomes through tailored treatment plans.

The second highest performing segment is hardware, with a focus on AI-optimized processors and data storage solutions that support complex computational needs. These technologies are pivotal in processing vast datasets required for predictive modeling. Additionally, cloud-based solutions are increasingly favored for their scalability and cost-effectiveness, although on-premise systems remain crucial for data-sensitive applications. The convergence of AI with biotechnology continues to unlock new opportunities, fostering innovation and driving market momentum. Enhanced collaboration between pharmaceutical companies and AI technology providers further accelerates this dynamic landscape.

The AI for Predictive Drug Response Modeling market is characterized by a dynamic landscape of market share distribution, pricing strategies, and new product launches. Companies are increasingly adopting innovative pricing models to capture greater market share, reflecting a keen understanding of customer needs and competitive pressures. The market is witnessing a surge in new product introductions, driven by rapid technological advancements and a growing demand for personalized medicine solutions. This has fostered an environment ripe for innovation, with firms striving to outpace competitors by continuously evolving their product offerings.

Competition in this market is fierce, with key players vying for dominance through strategic partnerships and acquisitions. Benchmarking against industry giants, smaller firms leverage niche expertise and agility to carve out market niches. Regulatory influences play a pivotal role, with stringent policies in North America and Europe shaping the competitive landscape. These regulations ensure high standards, yet also pose barriers to entry for new entrants. The market analysis reveals a trend towards increased regulatory harmonization, which could streamline operations and foster innovation across borders.

Geographical Overview:

The AI for Predictive Drug Response Modeling market is witnessing substantial growth across diverse regions. North America leads the charge, benefiting from advanced healthcare infrastructure and significant investments in AI research. The region's robust pharmaceutical sector is increasingly integrating AI to enhance drug efficacy and patient outcomes. Europe is not far behind, with its strong focus on precision medicine and AI-driven healthcare innovations.

The continent's regulatory frameworks support AI adoption, fostering a conducive environment for market expansion. Asia Pacific emerges as a promising growth pocket, driven by rapid technological advancements and a burgeoning pharmaceutical industry. Countries like China and India are at the forefront, investing heavily in AI to revolutionize drug development processes. Latin America and the Middle East & Africa are also gaining traction, with Brazil and the UAE emerging as key players. These regions are recognizing AI's potential to transform healthcare, paving the way for future growth.

Recent Developments:

In recent months, the AI for Predictive Drug Response Modeling Market has been marked by pivotal developments. Pfizer announced a collaboration with IBM to enhance their predictive modeling capabilities, leveraging AI to improve drug response predictions in clinical trials. This partnership aims to accelerate drug development timelines and reduce costs by utilizing advanced AI algorithms.

Roche has taken a strategic step by acquiring a minority stake in a promising AI startup specializing in predictive drug response. This investment underscores Roche's commitment to integrating cutting-edge AI technologies into their drug development processes, potentially revolutionizing personalized medicine.

In a significant regulatory update, the FDA has issued new guidelines for the integration of AI in predictive drug response modeling. These guidelines are designed to ensure the safety and efficacy of AI-driven predictions, providing a framework for companies to innovate while maintaining compliance.

AstraZeneca has launched an innovative AI platform designed to predict patient responses to cancer treatments. This platform utilizes machine learning to analyze vast datasets, offering oncologists valuable insights into treatment efficacy and patient outcomes.

Novartis has announced a joint venture with a leading tech company to develop AI-driven predictive models for rare diseases. This collaboration aims to address the unique challenges of rare disease drug development by harnessing AI's potential to predict patient responses more accurately.

Key Trends and Drivers:

The AI for Predictive Drug Response Modeling Market is expanding rapidly, driven by advancements in AI and machine learning. Enhanced computational power and sophisticated algorithms are enabling precise predictions of drug responses, significantly reducing research timelines. The integration of AI into drug discovery processes is becoming indispensable, as pharmaceutical companies strive for more efficient and cost-effective solutions.

Key trends include the growing adoption of personalized medicine, which leverages AI to tailor treatments to individual genetic profiles. This trend is further fueled by increasing investments in genomics and biotechnologies. Regulatory bodies are also adapting to these technological advancements, providing frameworks that encourage innovation while ensuring patient safety.

Furthermore, the collaboration between tech companies and healthcare providers is fostering the development of innovative AI-driven platforms. These partnerships aim to enhance predictive accuracy and improve patient outcomes. Opportunities abound for companies that can offer scalable, robust AI solutions, as the demand for predictive modeling in drug development continues to rise.

Restraints and Challenges:

The AI for Predictive Drug Response Modeling Market is currently grappling with several significant restraints and challenges. A primary challenge is the regulatory landscape's complexity, which hinders the swift integration of AI technologies into healthcare systems. Compliance with diverse international standards adds layers of difficulty, slowing market penetration. Furthermore, there is a notable shortage of skilled professionals adept in both AI and pharmacology, creating a bottleneck for innovation and implementation.

Data privacy concerns present another formidable barrier. Ensuring the confidentiality of sensitive medical data while leveraging AI for predictive modeling remains a critical issue. This challenge is exacerbated by varying global data protection regulations.

Moreover, the high cost of AI technology deployment limits its adoption, particularly among smaller pharmaceutical firms and research institutions. These costs include not only initial investments but also ongoing maintenance and updates.

Interoperability issues also pose a significant challenge. Integrating AI systems with existing healthcare infrastructure is often fraught with technical difficulties, impeding seamless operation.

Lastly, the market faces skepticism from healthcare professionals who may be reluctant to trust AI-generated predictions over traditional methods. Building confidence in AI's accuracy and reliability is essential for broader acceptance and utilization.

Key Companies:

Atomwise, Exscientia, Benevolent AI, Insilico Medicine, Recursion Pharmaceuticals, Numerate, Cyclica, Deep Genomics, Berg Health, GNS Healthcare, Bio Symetrics, Owkin, Standigm, Xtal Pi, Two XAR, Aria Pharmaceuticals, Aiforia Technologies, Verge Genomics, Aigenpulse, Quibim

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Component
  • 2.6 Key Market Highlights by Application
  • 2.7 Key Market Highlights by End User
  • 2.8 Key Market Highlights by Functionality
  • 2.9 Key Market Highlights by Deployment
  • 2.10 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Machine Learning
    • 4.1.2 Deep Learning
    • 4.1.3 Natural Language Processing
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Software Platforms
    • 4.2.2 AI Algorithms
    • 4.2.3 Data Management Tools
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Consulting
    • 4.3.2 Integration and Implementation
    • 4.3.3 Support and Maintenance
    • 4.3.4 Training and Education
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Cloud-based
    • 4.4.2 On-premise
    • 4.4.3 Hybrid
  • 4.5 Market Size & Forecast by Component (2020-2035)
    • 4.5.1 Hardware
    • 4.5.2 Software
    • 4.5.3 Services
  • 4.6 Market Size & Forecast by Application (2020-2035)
    • 4.6.1 Oncology
    • 4.6.2 Cardiology
    • 4.6.3 Neurology
    • 4.6.4 Infectious Diseases
    • 4.6.5 Immunology
  • 4.7 Market Size & Forecast by End User (2020-2035)
    • 4.7.1 Pharmaceutical Companies
    • 4.7.2 Biotechnology Firms
    • 4.7.3 Research Institutes
    • 4.7.4 Healthcare Providers
  • 4.8 Market Size & Forecast by Functionality (2020-2035)
    • 4.8.1 Predictive Analytics
    • 4.8.2 Data Mining
    • 4.8.3 Simulation
  • 4.9 Market Size & Forecast by Deployment (2020-2035)
    • 4.9.1 Large Enterprises
    • 4.9.2 SMEs
  • 4.10 Market Size & Forecast by Solutions (2020-2035)
    • 4.10.1 Customized Solutions
    • 4.10.2 Standard Solutions

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Component
      • 5.2.1.6 Application
      • 5.2.1.7 End User
      • 5.2.1.8 Functionality
      • 5.2.1.9 Deployment
      • 5.2.1.10 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Component
      • 5.2.2.6 Application
      • 5.2.2.7 End User
      • 5.2.2.8 Functionality
      • 5.2.2.9 Deployment
      • 5.2.2.10 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Component
      • 5.2.3.6 Application
      • 5.2.3.7 End User
      • 5.2.3.8 Functionality
      • 5.2.3.9 Deployment
      • 5.2.3.10 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Component
      • 5.3.1.6 Application
      • 5.3.1.7 End User
      • 5.3.1.8 Functionality
      • 5.3.1.9 Deployment
      • 5.3.1.10 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Component
      • 5.3.2.6 Application
      • 5.3.2.7 End User
      • 5.3.2.8 Functionality
      • 5.3.2.9 Deployment
      • 5.3.2.10 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Component
      • 5.3.3.6 Application
      • 5.3.3.7 End User
      • 5.3.3.8 Functionality
      • 5.3.3.9 Deployment
      • 5.3.3.10 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Component
      • 5.4.1.6 Application
      • 5.4.1.7 End User
      • 5.4.1.8 Functionality
      • 5.4.1.9 Deployment
      • 5.4.1.10 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Component
      • 5.4.2.6 Application
      • 5.4.2.7 End User
      • 5.4.2.8 Functionality
      • 5.4.2.9 Deployment
      • 5.4.2.10 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Component
      • 5.4.3.6 Application
      • 5.4.3.7 End User
      • 5.4.3.8 Functionality
      • 5.4.3.9 Deployment
      • 5.4.3.10 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Component
      • 5.4.4.6 Application
      • 5.4.4.7 End User
      • 5.4.4.8 Functionality
      • 5.4.4.9 Deployment
      • 5.4.4.10 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Component
      • 5.4.5.6 Application
      • 5.4.5.7 End User
      • 5.4.5.8 Functionality
      • 5.4.5.9 Deployment
      • 5.4.5.10 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Component
      • 5.4.6.6 Application
      • 5.4.6.7 End User
      • 5.4.6.8 Functionality
      • 5.4.6.9 Deployment
      • 5.4.6.10 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Component
      • 5.4.7.6 Application
      • 5.4.7.7 End User
      • 5.4.7.8 Functionality
      • 5.4.7.9 Deployment
      • 5.4.7.10 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Component
      • 5.5.1.6 Application
      • 5.5.1.7 End User
      • 5.5.1.8 Functionality
      • 5.5.1.9 Deployment
      • 5.5.1.10 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Component
      • 5.5.2.6 Application
      • 5.5.2.7 End User
      • 5.5.2.8 Functionality
      • 5.5.2.9 Deployment
      • 5.5.2.10 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Component
      • 5.5.3.6 Application
      • 5.5.3.7 End User
      • 5.5.3.8 Functionality
      • 5.5.3.9 Deployment
      • 5.5.3.10 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Component
      • 5.5.4.6 Application
      • 5.5.4.7 End User
      • 5.5.4.8 Functionality
      • 5.5.4.9 Deployment
      • 5.5.4.10 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Component
      • 5.5.5.6 Application
      • 5.5.5.7 End User
      • 5.5.5.8 Functionality
      • 5.5.5.9 Deployment
      • 5.5.5.10 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Component
      • 5.5.6.6 Application
      • 5.5.6.7 End User
      • 5.5.6.8 Functionality
      • 5.5.6.9 Deployment
      • 5.5.6.10 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Component
      • 5.6.1.6 Application
      • 5.6.1.7 End User
      • 5.6.1.8 Functionality
      • 5.6.1.9 Deployment
      • 5.6.1.10 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Component
      • 5.6.2.6 Application
      • 5.6.2.7 End User
      • 5.6.2.8 Functionality
      • 5.6.2.9 Deployment
      • 5.6.2.10 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Component
      • 5.6.3.6 Application
      • 5.6.3.7 End User
      • 5.6.3.8 Functionality
      • 5.6.3.9 Deployment
      • 5.6.3.10 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Component
      • 5.6.4.6 Application
      • 5.6.4.7 End User
      • 5.6.4.8 Functionality
      • 5.6.4.9 Deployment
      • 5.6.4.10 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Component
      • 5.6.5.6 Application
      • 5.6.5.7 End User
      • 5.6.5.8 Functionality
      • 5.6.5.9 Deployment
      • 5.6.5.10 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Atomwise
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Exscientia
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Benevolent AI
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Insilico Medicine
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Recursion Pharmaceuticals
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Numerate
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Cyclica
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Deep Genomics
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Berg Health
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 GNS Healthcare
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Bio Symetrics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Owkin
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Standigm
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Xtal Pi
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Two XAR
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Aria Pharmaceuticals
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Aiforia Technologies
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Verge Genomics
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Aigenpulse
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Quibim
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us